MSD, Samsung's Glargine Biosimilar Hits Phase III Endpoints
This article was originally published in PharmAsia News
MSD has unveiled positive new results from two Phase III clinical trials with its investigational insulin glargine biosimilar, and the progress is set to further accelerate the commercialization of the diverse biosimilar pipeline at partner Samsung Bioepis, which is partially funding development of the product.
You may also be interested in...
Among the Korean firms presenting at J.P. Morgan, Hanmi laid out its strategy for obesity and other core pipeline assets, Celltrion focused on its expanding biosimilar pipeline and China plans and LG Chem unveiled new R&D progress.
BeiGene licenses antibody therapeutics for Castleman’s disease and high-risk neuroblastoma.
After a year full of disappointing and unexpected events, the South Korean pharma sector is hoping for a turnaround in 2020, with expected biosimilar launches in global markets, progress in drug pipelines, large IPOs and implementation of a new law on cutting-edge biologics.